Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.


Confirmed Presenting Companies:

 Speaker Profile

CEO, Scipher Medicine

Biography
Alif is a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies. Alif and his team have spent the last decade pioneering a network medicine platform – a powerful tool that has the potential to predict patient response to targeted therapies, develop precision diagnostics and repurpose previously approved drugs. A Swedish national with a perspective on global healthcare systems, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas - raising over $225M in venture and private equity capital. Alif is an experienced speaker and writer on healthcare topics and was recently featured on The Bio Report podcast (“Bringing Precision Medicine to Autoimmune Disease”), at the BIO International Convention (“Precision Medicine Outside Oncology: One Size Does Not Fit All),” and on Morning Consult (“Addressing Healthcare’s Largest Hidden Cost: Drug Nonresponse”).


Genomic Profiling Showcase:
Scipher Medicine

Scipher Medicine is committed to transforming the way healthcare prioritizes drugs for patients. Our first product, PrismRA, is a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to the world's best-selling drug class: TNF inhibitors.

Bringing Precision Medicine To Autoimmune Disease
In rheumatoid arthritis, only 1 in 3 patients respond to the top biologic therapies. Scipher Medicine’s PrismRA test identifies patients who are less likely to respond to TNFi therapies, allowing patients to optimize drug class selection prior to treatment.

 Speaker Profile

Ph.D., CEO, Ciscovery Bio

Biography
Before founding Ciscovery Bio, Dr. Joonyul Kim had managed Proximity Biosciences as the founder CEO for 5 yrs. While at the company, he received multiple federal/state fundings including NSF STTR Phase I, and made research contracts with drug discovery companies.


Genomic Profiling Showcase:
Ciscovery Bio

Ciscovery Bio is a non-coding biomarker company that discovers and utilizes cis-regulatory modules for drug development and treatment.

Cis-regulatory Modules as Non-coding Biomarkers
Cis-regulatory modules (CRMs) are highly sensitive sensors for drug-induced cellular changes and strong candidates for precision medicine, but most of them still remain unexplored. Our genome-scale CRM discovery tool enabled more than 100,000 functionally-validated CRMs for profiling drugs and for searching the variants.

 Speaker Profile

Ph.D., M.D., Chief Medical Officer, Beverly Hills Institute for Precision Medicine

Biography
Dr. Stanford’s clinical practice is focused on providing consultative services to primary care providers for the purposes of the integration of precision medicine into primary care plans. This approach is novel from its comprehensive nature and practical real-world implementation. Dr. Stanford began his career as a Mechanical/Aerospace Engineer at Texas Instruments in 1982. In 1991, he pivoted into biomedical science and completed the physician-scientist training program (MD/PhD) at UCLA in 1998 and internal medicine residency at UCLA in 2001. Dr. Stanford was one of the pioneers in the field of hospital medicine. In 2002, he founded and led a 25-physician group of private practice hospitalists at Cedars-Sinai Medical Center in Los Angeles and was elected by his peers to be Clinical Chief of General Internal Medicine. He completed Professional Certification in Genetics and Genomics through Stanford University in 2018 and subsequently founded the Beverly Hills Institute for Precision Medicine.


Genomic Profiling Showcase:
Beverly Hills Institute for Precision Medicine

BHIPM provides comprehensive consultative services to primary care providers and their patients for the purposes of integrating precision medicine recommendations into primary care plans.

Precision Medicine Consultation in Primary Care
This presentation provides an overview of the consultative approach taken by BHIPM in using whole genome sequencing and analysis, alongside the patient's comprehensive past medical history, extended family medical history and recent biochemical studies to inform personalized primary care plans.

 Speaker Profile

Chief Operating Officer, Pacific Biosciences

Biography
Mark recently joined Pacific Biosciences in the newly created role of Chief Operating Officer where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities. Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees. He joined Illumina in 2006 as a regional account manager in Illumina’s sales organization, and advanced rapidly taking on senior commercial leadership roles with ever increasing areas of responsibility, ultimately assuming the Chief Commercial Officer role in 2017. During his fifteen year tenure at Illumina, he was instrumental in scaling Illumina’s global commercial organization, representing the voice of their customers and driving significant annual revenue growth. Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics. He earned as B.S. in Biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.


Genomic Profiling Showcase:
Pacific Biosciences

PacBio highly accurate long-read sequencing provides the most comprehensive view of genomes, transcriptomes, and epigenomes- including the full spectrum of genetic variation

 Speaker Profile

Ph.D., Vice President, Data Science, Engineering, and Operations, ChromaCode, Inc.

Biography
Chris is an experienced engineer and manager in the life sciences industry focused on data science, product engineering, and process development. Most recently, he was an engineering manager at Illumina, leading the development of processes for consumables manufacturing across several major platforms, including the HiSeqX nanopatterned flowcell which enabled the $1000 genome.


Genomic Profiling Showcase:
ChromaCode, Inc.

ChromaCode is a software and reagent technology company with a focus on bioinformatics aimed at pioneering advancements in precision diagnostics by integrating reliable biochemical techniques with computational mathematics to enhance performance in testing, at a very low cost.

HDPCR™: Multiplexing Multiplied
ChromaCode expands utility of multiplexed PCR in genomic applications for NIPT and oncology through a unique combination of chemistry and data science. HDPCR™ yields 20-plex in a single well on qPCR and offers exponential utility on digital PCR platforms.

 Speaker Profile

Ph.D., CEO, Gencove Inc.

Biography
TBA


 Speaker Profile

Ph.D., CSO, Clear Labs

Biography
As Chief Scientific Officer for Clear Labs, I lead the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, I prioritize team culture and empower my team members to maximize their talents and push the bounds of what’s possible. As a scientist and researcher, I have deep insights into the world of health, biotechnology, and next-generation sequencing, and I continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. I want to leave a legacy by raising the quality of life and health of the world’s population. Through my work at Clear Labs, we have made a huge impact on food safety. I aim to expand that impact by using my skills to improve clinical and pharmaceutical genomics and their effectiveness in public health.